| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/16/2011 | US20110142941 Nanoparticle and Polymer Formulations for Thyroid Hormone Analogs, Antagonists, and Formulations and Uses Thereof |
| 06/16/2011 | US20110142938 Nanotubes as Mitochondrial Uncouplers |
| 06/16/2011 | US20110142919 Cytotoxic T-Lymphocyte-Inducing Immunogens for Prevention, Treatment and Diagnosis of Cancer |
| 06/16/2011 | US20110142918 Anti-angiogenic compositions and therapeutic applications thereof |
| 06/16/2011 | US20110142915 Compositions and methods for inhibition of vegf |
| 06/16/2011 | US20110142914 Inhalable compositions having enhanced bioavailability |
| 06/16/2011 | US20110142912 Non-specific immunostimulating agents |
| 06/16/2011 | US20110142904 Methods for the In Situ Treatment of Bone Cancer |
| 06/16/2011 | US20110142901 Sustained release composition |
| 06/16/2011 | US20110142887 Methods and compositions for liquidation of tumors |
| 06/16/2011 | US20110142886 Pegylated polyplexes for polynucleotide delivery |
| 06/16/2011 | US20110142884 Materials and Methods for Making Improved Micelle Compositions |
| 06/16/2011 | US20110142880 Lentivirus-based immunogenic vectors |
| 06/16/2011 | US20110142873 Bioactive purified hspe7 compositions |
| 06/16/2011 | US20110142867 Immunotherapeutic methods and systems |
| 06/16/2011 | US20110142865 Tumor-associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules |
| 06/16/2011 | US20110142864 Tumor-associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules |
| 06/16/2011 | US20110142859 Antibodies and immunoconjugates and uses therefor |
| 06/16/2011 | US20110142856 Compound containing basic group and use thereof |
| 06/16/2011 | US20110142853 Engineered Anti-IL-23p19 Antibodies |
| 06/16/2011 | US20110142852 Multispecific antibodies |
| 06/16/2011 | US20110142851 IL6 Immunotherapeutics |
| 06/16/2011 | US20110142848 Anti-beta-2-microglobulin agents and the use thereof |
| 06/16/2011 | US20110142844 Anti-Extended Type I Glycosphingolipid Antibody, Derivatives Thereof And Use |
| 06/16/2011 | US20110142842 Polypeptides |
| 06/16/2011 | US20110142840 Compositions and Methods for Diagnosing and Treating Cancer |
| 06/16/2011 | US20110142829 Anti-tumour compositions and methods |
| 06/16/2011 | US20110142828 Treatment prediction involving hmgcr |
| 06/16/2011 | US20110142827 Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels |
| 06/16/2011 | US20110142826 Azaindolizines and methods of use |
| 06/16/2011 | US20110142825 Glycosylation Engineering of Antibodies for Improving Antibody-Dependent Cellular Cytotoxicity |
| 06/16/2011 | US20110142822 Crystal of egfr extracellular domain and cetuximab fab fragment, and uses thereof |
| 06/16/2011 | US20110142821 Roles for dual endothelin-1/angiotensin ii receptor (dear) in hypertension and angiogenesis |
| 06/16/2011 | US20110142815 Compounds, composition, methods, targets for cancer therapy |
| 06/16/2011 | US20110142813 Use Of Anti-Cancer Cell Composition For Treatment Of Head And Neck Cancer, Which Is Intended To Be Administered To Nutrient Artery Of Tumor |
| 06/16/2011 | US20110142811 Measles virus for the elimination of unwanted cell populations |
| 06/16/2011 | US20110142801 Protease resistant modified interferon-beta polypeptides and their use in treating diseases |
| 06/16/2011 | US20110142796 Fused Pyridine, Pyrimidine and Triazine Compounds as Cell Cycle Inhibitors |
| 06/16/2011 | US20110142794 Methods and Compositions to Determine the Chemosensitizing Dose of Suramin Used in Combination Therapy |
| 06/16/2011 | US20110142792 Compositions for Increasing Polypeptide Stability and Activity, and Related Methods |
| 06/16/2011 | US20110142791 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
| 06/16/2011 | US20110142769 Low toxicity topical active agent delivery system |
| 06/16/2011 | US20110142764 Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases |
| 06/16/2011 | US20110142763 Megalin-Based Delivery of Therapeutic Compounds to the Brain and Other Tissues |
| 06/16/2011 | US20110142761 Il-1 binding proteins |
| 06/16/2011 | US20110142760 Psma-binding agents and uses thereof |
| 06/16/2011 | US20110142757 Novel compounds and their uses in diagnosis |
| 06/16/2011 | US20110142756 Method And Composition For The Treatment Of Cancer By The Enzymatic Conversion Of Soluble Radioactive Toxic Precipitates In The Cancer |
| 06/16/2011 | US20110139654 Oxadiazole derivatives for the treatment of diabetes |
| 06/16/2011 | US20110138888 Treatment of obesity |
| 06/16/2011 | CA2836117A1 Oncolytic rhabdovirus |
| 06/16/2011 | CA2821034A1 Method of treating pancreatic cancer |
| 06/16/2011 | CA2785996A1 Sr-bi as a predictor of human female infertility and responsiveness to treatment |
| 06/16/2011 | CA2784005A1 Nanoparticle carrier systems based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy (pdt) |
| 06/16/2011 | CA2784001A1 Nanoparticle carrier systems based on human serum albumin for photodynamic therapy |
| 06/16/2011 | CA2783678A1 Neutralizing prolactin receptor antibodies and their therapeutic use |
| 06/16/2011 | CA2783654A1 Neutralizing prolactin receptor antibodies and their therapeutic use |
| 06/16/2011 | CA2783651A1 Neutralizing prolactin receptor antibodies and their therapeutic use |
| 06/16/2011 | CA2783610A1 Neutralizing prolactin receptor antibodies and their therapeutic use |
| 06/16/2011 | CA2783535A1 Stable formulations for lyophilizing therapeutic particles |
| 06/16/2011 | CA2783514A1 Neutralizing prolactin receptor antibodies and their therapeutic use |
| 06/16/2011 | CA2783513A1 Neutralizing prolactin receptor antibodies and their therapeutic use |
| 06/16/2011 | CA2783338A1 Anti-c4.4a antibodies and uses thereof |
| 06/16/2011 | CA2782624A1 Therapeutic use of protein-polymer conjugates |
| 06/16/2011 | CA2782248A1 Bis-acylated hydroxylamine derivatives |
| 06/16/2011 | CA2782132A1 Methods and compositions using peroxiredoxin 1 (prx1) as an adjuvant |
| 06/16/2011 | CA2781888A1 Agents and methods for treating ischemic and other diseases |
| 06/16/2011 | CA2781717A1 Dock-and-lock (dnl) complexes for delivery of interference rna |
| 06/16/2011 | CA2781431A1 Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof |
| 06/16/2011 | CA2781311A1 Methods for enhancing anti-tumor antibody therapy |
| 06/16/2011 | CA2781218A1 Heterocyclic sulfonamide derivatives |
| 06/16/2011 | CA2780692A1 Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| 06/16/2011 | CA2777907A1 Fluoro-substituted 2-aryl-3,5-dicyano-4-indazolyl-6-methyl-1,4-dihydropyridines and uses thereof |
| 06/15/2011 | EP2333065A1 Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1 |
| 06/15/2011 | EP2333064A1 Nucleotide and protein sequences of Nogo genes and methods based thereon |
| 06/15/2011 | EP2333052A1 Desaturase genes and uses thereof |
| 06/15/2011 | EP2332995A1 Neutralizing prolactin receptor antibodies and their therapeutic use |
| 06/15/2011 | EP2332993A1 Human monoclonal antibody to the human epidermal growth factor receptor |
| 06/15/2011 | EP2332990A1 Human anti-epidermal growth factor receptor antibody |
| 06/15/2011 | EP2332978A1 Novel polypeptides involved in immune response |
| 06/15/2011 | EP2332976A1 Novel polypeptides involved in immune response |
| 06/15/2011 | EP2332973A2 Differential in tumour gene products and use of same |
| 06/15/2011 | EP2332964A1 Apoptotically active peptides |
| 06/15/2011 | EP2332962A1 Cyclopenta[g]quinazoline compounds for use in the treatment of inflammatory or allergic conditions |
| 06/15/2011 | EP2332952A1 Modified 2' and 3'-nucleoside prodrugs for treating flaviridae infections |
| 06/15/2011 | EP2332950A1 Epothilone glycoside compounds, compositions containing epothilone glycoside compounds as active components and uses thereof |
| 06/15/2011 | EP2332939A1 Novel Naphthyridine derivatives and the use thereof as kinase inhibitors |
| 06/15/2011 | EP2332934A1 Chrystals including a malic acid salt of N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof |
| 06/15/2011 | EP2332924A1 Pyrimidine derivates, medicaments comprising them, their use and process of their preparation |
| 06/15/2011 | EP2332922A1 N-substituted azoles and their use as MEK-1 and/or ERK-2 modulators |
| 06/15/2011 | EP2332917A1 Compounds for PIM kinase inhibition and for treating malignancy |
| 06/15/2011 | EP2332579A2 Antibodies that bind human interleukin-18 and methods of making and using |
| 06/15/2011 | EP2332576A1 Immunotherapy of B-cell malignancies using anti-CD22 antibody conjugates |
| 06/15/2011 | EP2332575A1 Treatment of cancer with novel anti-IL 13 monoclonal antibodies |
| 06/15/2011 | EP2332561A1 Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| 06/15/2011 | EP2332560A1 Use of a neurofilament peptide for the treatment of glioma |
| 06/15/2011 | EP2332551A1 Use of thioarabinofuranosyl compounds |
| 06/15/2011 | EP2332550A1 Tetracyclines for the treatment of neurodegenerative diseases |
| 06/15/2011 | EP2332549A1 Novel tetracyclines and their use in medicine |
| 06/15/2011 | EP2332548A1 Tetracyclines for the treatment of stroke |